Results 111 to 120 of about 16,636 (201)

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

, 2004
Background. Invasive aspergillosis (IA) is an important cause of morbidity and mortality among immuno-compromised patients. Echinocandins are novel antifungal molecules with in vitro and in vivo activity against Aspergillus species. Methods.
Walsh, TJ, D, Petrikkos, G, Raad, I, Selleslag, Sable, CA, Maertens, J, Denning, DW, Boogaerts, M, Patterson, TF, Petersen, FB, Ngai, A, Kartsonis, NA, Taylor, A, Caspofungin Salvage Aspergillosis   +14 more
core  

Caspofungin

Reactions Weekly, 2021
Sujata Dwivedi, Shivaprakash M Rudramurthy   +1 more
openaire   +2 more sources

Walsh & Hoyt: Caspofungin

, 2005
Caspofungin is the first approved agent from a class of antifungal agents called the echinocandins. Its mechanism of action is unique in that it attacks the cell wall of the fungus, as opposed to its cell membrane.
Joel M. Weinstein, MD
core  

Fpr1p mediates the synergistic effect of rapamycin or tacrolimus with caspofungin in <i>Clavispora lusitaniae in vitro</i>. [PDF]

JAC Antimicrob Resist
Lefranc M, Accoceberry I, Fitton-Ouhabi V, Biteau N, Noël T.   +4 more
europepmc   +1 more source

Caspofungin-Based Red-Emissive Probes for Fluorescent Imaging of Pathogenic Fungi. [PDF]

JACS Au
Klausen M, Sharma R, Brown JL, Ramage G, Bradley M.   +4 more
europepmc   +1 more source

Repurposing caspofungin as a small-molecule inhibitor of Clostridium perfringens α-toxin for treatment of gas gangrene. [PDF]

Commun Med (Lond)
Takehara M, Homma Y, Ishihara T, Sakaguchi Y, Kasai Y, Matsumoto K, Nakashima K, Yamaji T, Tanaka Y, Imagawa H, Nagahama M.   +10 more
europepmc   +1 more source

Immunological fitness of echinocandin-resistant <i>Nakaseomyces glabratus</i> (former <i>Candida glabrata</i>): The impact on the management of candidemia. [PDF]

Virulence
Basmaciyan L, Alvarez-Rueda N, Aldebert D, Sahnouni H, Garnaud C, Patarot D, Ducreux A, Bon F, Winckler P, Le Pape P, Cornet M, Dalle F.   +11 more
europepmc   +1 more source

Correction: Adaptive morphological changes link to poor clinical outcomes by conferring echinocandin tolerance in Candida tropicalis. [PDF]

PLoS Pathog
Wu Y, Zou Y, Dai Y, Lu H, Zhang W, Chang W, Wang Y, Nie Z, Wang Y, Jiang X.   +9 more
europepmc   +1 more source

Evaluation of Sensititre YeastOne for antifungal susceptibility testing of <i>Candida (Candidozyma) auris</i>: misclassification of <i>FKS1</i> mutants and overestimation of caspofungin resistance in a global collection of isolates. [PDF]

J Clin Microbiol
Siopi M, Leventaki S, Pachoulis I, Rentoumi A, Argyris N, Spruijtenburg B, Meijer EFJ, Meis JF, Pournaras S, Tsakris A, Vrioni G, Meletiadis J.   +11 more
europepmc   +1 more source

Harnessing random peptide mixtures to combat multidrug-resistant fungal infections. [PDF]

mBio
Adeoye J, Belo Y, Rocha MC, Hayby H, Israyilova A, Hayouka Z, Shlezinger N.   +6 more
europepmc   +1 more source